Related Experiment Video
Updated: Jan 13, 2026
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Advances in novel modification strategies for enhancing the tumor tissue specificity of PROTACs
Liuzhi Hu1, Shuang Wu1, Wentao Wang1
1College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
Abstract:
Proteolysis-Targeting Chimeras (PROTACs), a pioneering Targeted Protein Degradation (TPD) technology, have emerged as a powerful therapeutic modality for cancer by mediating the degradation of proteins via the ubiquitin-proteasome system. Despite their promise, the clinical translation of PROTACs is frequently hampered by significant challenges, including suboptimal pharmacokinetic properties, poor stability, and most critically, a lack of tumor specificity, which can lead to on-target, off-tumor toxicities and a narrow therapeutic window. To address these limitations, a variety of innovative strategies have been developed to enhance the tumor-specific accumulation of PROTACs. This review provides a comprehensive overview of the recent advances in this field. We systematically discuss three major approaches: intrinsic structural modifications of the PROTAC scaffold to confer tissue selectivity; the design of activatable prodrugs that respond to the unique tumor microenvironment; and the development of intelligent nano-delivery systems for targeted release. Collectively, these next-generation modification strategies aim to maximize the therapeutic index of PROTACs by improving their efficacy and safety profiles. This review highlights the technological pathways poised to accelerate the clinical development of tissue-specific protein degraders for oncology.
Insights
Proteolysis-Targeting Chimeras (PROTACs) offer cancer therapy by degrading proteins. New strategies enhance PROTAC tumor specificity, aiming to improve efficacy and reduce side effects for better cancer treatment.
Area of Science:
- Oncology
- Biochemistry
- Drug Discovery
Background:
- Proteolysis-Targeting Chimeras (PROTACs) are a novel Targeted Protein Degradation (TPD) technology for cancer therapy.
- PROTACs utilize the ubiquitin-proteasome system to degrade target proteins.
- Clinical translation faces challenges like poor pharmacokinetics, stability, and tumor specificity, leading to toxicities.
Purpose of the Study:
- To provide a comprehensive overview of recent advances in enhancing tumor-specific accumulation of PROTACs.
- To discuss strategies for overcoming limitations in PROTAC clinical translation.
- To highlight pathways accelerating the development of tissue-specific protein degraders for oncology.
Main Methods:
- Review of intrinsic structural modifications for tissue selectivity.
- Discussion of activatable prodrugs responding to the tumor microenvironment.
- Exploration of intelligent nano-delivery systems for targeted release.
Main Results:
- Innovative strategies are being developed to improve PROTAC tumor specificity.
- These strategies include scaffold modifications, prodrug design, and nano-delivery systems.
- Next-generation modifications aim to maximize the therapeutic index of PROTACs.
Conclusions:
- Enhanced tumor specificity is crucial for maximizing the efficacy and safety of PROTACs.
- Advanced strategies promise to improve the therapeutic window and reduce off-tumor toxicities.
- These developments are poised to accelerate the clinical application of targeted protein degraders in cancer treatment.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...